Nineteen children with mycoplasmic pneumonia who were treated with western medicine until CRP values became negative and who had coughing and dry mouth were treated with the Makyo-kanseki-to extract in a daily dose of 2-3g in addition to Western medicine (Kampo combination group). They visited my clinic in 1992 and 1993. Sixteen children with mild mycoplasmic pneumonia were treated with western medicine alone at the Department of Pediatrics, Chiba Municipal Kaihin Hospital (Western medicine group). Antibacterial agents included oral ricamycin or minomycin. Diagnosis was made when the mycoplasma antibody titer (CF, HA) in the paired serum was four-fold or more. Coughing disappeared in all patients in the Kampo combination group after Makyo-kanseki-to was added for a period of two to four days. The mean duration of administration of the antibacterial agent was 7. 1±1.3 days and the mean duration required to eliminate coughing was 10.2±1.2 days. Both figures were lower than those in the Western medicine group, namely 10.8±2.0 days and 12.3±4.7 days respectively (P₁<0.0001, P₂=0.06). It occurred to me that coughing and dry mouth, which are noted during the recovery stage of mycoplasmic pneumonia in children, are primary symptoms for which Makyo-kanseki-to is indicated. This formulation indeed improved these symptoms. The results suggest that Makyo-kanseki-to may be useful for coughing in mycoplasmic pneumonia.

Keishi-ka-ogi-to or Keishi-ka-ryukotsu-borei-to was administered to two patients with bronchia asthma. Patient 1 was a 52-year-old woman, and patient 2 was a 40-year-old man. In both cases, asthma attacks began in adulthood and occurred in any season. According to the criterion of asthma severity established by the Japanese Society of Allergology, patient 1 was severe and patient 2 was moderate. Patient 1 was in the condition of hypofunctioning (Kyo-Sho), and her asthmatic state was improved with administration of the Kampo extract, Keishi-ka-ogi-to, which is a kind of Ho-zai. Patient 2 was a case of psycho-modified asthma and his asthmatic state was improved with administration of the Kampo extract, Keishi-ka-ryukotsu-borei-to, which is a kind of tranquilizer (An-shin-zai).

Twelve male patients with gout in the remission stage were administered Boiogi-to extract (5.0g/day), Mokutsu (Akebia quinata) extract (0.5g/day) and Shazenshi (Plantago asiatica) extract (0.5g/day) twice a day, The efficacy of this combination was then evaluated. (Prior to commencement of this study, all patients carried both diet and exercise therapies and contniued them during this study).
After the 12-week administration period was completed, significant results were observed. Notably, there was a decrease of body weight, decrease in serum uric acid and serum glycerol, and an increase in serum HDL-cholesterol. By the 24th week after therapy commencement, the body weight did not increase and the serum uric acid did not elevate. No side effects and no gout attacks ware reported. The clinical symptoms of fatigue, hidrosis, oliguria, and edema also improved. In conclusion, this kampo formula was considered to be effective in the treatment of gout.